Crossbow Therapeutics Doses First Patient in CBX-663 Phase 1
CAMBRIDGE, Mass. — September 9, 2026 Crossbow Therapeutics, Inc. announced dosing of the first participant in the Phase 1...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, Mass. — September 9, 2026 Crossbow Therapeutics, Inc. announced dosing of the first participant in the Phase 1...
